FDA approves drug that doubles survival for advanced pancreatic cancer
The US FDA has approved daraxonrasib for metastatic pancreatic cancer after trials showed it doubled survival compared to chemotherapy.
We haven't written up this one. Ajel English has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- FDA approves new pancreatic cancer drug months ahead of schedule arabianbusiness.com